AOD-9604 and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide

What Is AOD-9604 and How Is It Administered?

AOD-9604, also called HGH fragment 176-191, is a synthetic peptide comprising the carboxy-terminal 16 amino acids of human growth hormone. Researchers initially studied it at Monash University for its fat-metabolism effects without the insulin-desensitizing properties of full-length growth hormone. It has not received FDA approval for any indication and is dispensed in the United States only through 503A compounding pharmacies for individual patient use.

Routes of Administration

Three routes are used in clinical compounding practice:

• Subcutaneous injection. The most common route. The peptide enters systemic circulation directly, bypassing the gastrointestinal tract.
• Sublingual tablet or troche. Absorbed partly through oral mucosa and partly through gastric mucosa after swallowing.
• Oral capsule. Least common. Absorption depends on gastric and intestinal conditions.

The route chosen has the single largest influence on whether a PPI creates any clinically meaningful interaction.

Peptide Stability and Gastric pH

Peptides are subject to acid hydrolysis and enzymatic degradation in the stomach [1]. Gastric pH in a fasted adult averages 1.5 to 3.5 [2]. At that pH, peptide bonds can denature before absorption occurs. PPIs raise fasting gastric pH to above 4.0, and in some patients above 6.0, within five days of daily dosing [3]. Whether a higher gastric pH benefits or harms peptide absorption depends on the specific peptide's stability profile.

How PPIs (Omeprazole and Pantoprazole) Work

Omeprazole (Prilosec, 20 mg once daily standard dose) and pantoprazole (Protonix, 40 mg once daily standard dose) irreversibly inhibit the H+/K+-ATPase proton pump in gastric parietal cells [4]. Acid suppression begins within one hour of the first dose and reaches steady-state after three to five days of continuous use [4].

CYP450 Metabolism of PPIs

Both drugs are metabolized primarily by cytochrome P450 2C19 (CYP2C19) and secondarily by CYP3A4 [5]. CYP2C19 poor metabolizers reach omeprazole plasma concentrations approximately three-fold higher than extensive metabolizers [5]. Pantoprazole carries a slightly lower CYP2C19 inhibition potential than omeprazole, which is one reason clinicians prefer it when minimizing DDI risk [6].

P-glycoprotein and AOD-9604

P-glycoprotein (P-gp) is a membrane efflux transporter that limits the intestinal absorption of many drugs. Omeprazole is not considered a clinically significant P-gp inhibitor at therapeutic doses [7]. AOD-9604, as a small peptide, has not been evaluated as a P-gp substrate in peer-reviewed literature. No published transporter-interaction study exists for this compound.

The Absorption Interaction: Mechanism and Clinical Significance

The theoretical interaction between AOD-9604 and PPIs centers on gastric pH, not on enzyme competition or transporter overlap. This distinction matters for route-specific counseling.

Subcutaneous AOD-9604 Plus a PPI

Subcutaneous injection delivers AOD-9604 directly into the interstitial space beneath the skin. The compound enters lymphatic channels and then systemic circulation. Gastric pH is irrelevant. For patients on omeprazole 20 mg or pantoprazole 40 mg who inject AOD-9604 subcutaneously, no pharmacokinetic interaction is expected based on established absorption principles [8].

Oral or Sublingual AOD-9604 Plus a PPI

This is where the interaction becomes theoretically meaningful. Oral peptide bioavailability is generally poor to begin with; studies on oral GLP-1 receptor agonists (which are also peptides) show bioavailability below 1% without dedicated absorption enhancers [9]. When gastric pH rises above 4.0 on a PPI, two competing effects occur:

1. Reduced acid hydrolysis, which might preserve peptide integrity.
2. Reduced pepsin activity (pepsin requires pH <4 for maximum activity), which also might preserve peptide structure [10].

The net effect on AOD-9604 oral absorption is unknown. No PK study has been published. The clinical assumption used in 503A compounding practice is that gastric pH changes from standard PPI doses produce minimal impact on the total absorbed fraction of sublingual AOD-9604, because the dominant absorption window for sublingual formulations is the buccal and sublingual mucosa rather than the stomach [11].

Why No Pharmacodynamic Interaction Exists

AOD-9604 binds to beta-3 adrenergic receptors in adipose tissue and stimulates lipolysis through a pathway distinct from gastric acid regulation [12]. PPIs act exclusively on parietal cell H+/K+-ATPase. The two drugs have no overlapping receptor targets, no shared signaling cascade, and no documented pharmacodynamic interaction.

CYP2C19 and AOD-9604: Is There an Enzyme Competition Problem?

CYP2C19 poor metabolizer status (approximately 2 to 5 percent of Northern European populations, and up to 15 percent of East Asian populations) leads to significantly higher omeprazole exposure [13]. Pantoprazole is less sensitive to CYP2C19 genotype than omeprazole [6]. These PPI pharmacokinetics affect the degree of acid suppression achieved, which in turn affects how much gastric pH rises.

AOD-9604 has not been identified as a CYP2C19 substrate, inhibitor, or inducer in any published in vitro or in vivo study. The FDA Drug Interaction Studies Guidance recommends in vitro screening for all new molecular entities, but AOD-9604 is not a registered FDA new molecular entity and has not undergone that process [14].

The practical takeaway: there is no known enzyme competition between AOD-9604 and either omeprazole or pantoprazole.

What the FDA Labels Say

The FDA-approved label for omeprazole (NDA 019810) lists interactions with drugs whose absorption is pH-dependent, including atazanavir, nelfinavir, and erlotinib [15]. Peptides are not addressed. The pantoprazole label (NDA 020987) similarly focuses on pH-sensitive small molecules and CYP2C19 substrates [16]. Neither label references peptide therapies, compounded or otherwise, which is expected given that AOD-9604 has never completed a formal NDA or IND process with the FDA.

The absence of a label warning should not be read as a clearance. It reflects a data gap, not a proven safety finding.

Severity Classification: How Serious Is This Interaction?

Standard DDI severity scales (Lexicomp, Micromedex, Clinical Pharmacology) classify interactions by the level of evidence and the potential for patient harm. Applying those criteria mechanistically:

• Interaction type: absorption-based, pH-mediated (theoretical)
• Evidence level: theoretical/mechanistic only, no clinical PK study
• Clinical significance: low for subcutaneous AOD-9604, low-to-moderate theoretical concern for oral/sublingual formulations
• Action required: no dose adjustment, no drug separation required for subcutaneous route; for oral/sublingual, administering AOD-9604 at least 30 minutes before the PPI on an empty stomach may optimize absorption [17]

A 2016 systematic review in the British Journal of Clinical Pharmacology found that gastric pH elevation by PPIs reduced the absorption of 12 pH-sensitive drugs by an average of 37 percent [18]. Whether AOD-9604 oral formulations would show a similar reduction is unknown, but the mechanism is plausible.

Monitoring and Patient Counseling

What to Monitor

No specific laboratory monitoring is indicated for this drug combination. AOD-9604 does not require therapeutic drug monitoring, and PPIs at standard doses do not alter any panel routinely ordered in a peptide therapy practice.

Clinicians should monitor:

• Body composition response. If a patient on a PPI switches from subcutaneous to oral AOD-9604 and reports reduced efficacy, reduced absorption from pH changes is one possible explanation [19].
• GI symptoms. Both PPIs and oral peptide formulations can alter GI motility. Overlapping GI effects (bloating, altered transit) should be attributed carefully [20].
• Magnesium levels. Long-term PPI use (over one year) is associated with hypomagnesemia, per FDA safety communication issued in 2011 [21]. This is unrelated to AOD-9604 but relevant for patients on extended PPI therapy.

Timing Recommendations for Oral or Sublingual AOD-9604

If a patient insists on an oral or sublingual formulation while taking a once-daily PPI:

1. Take the PPI after waking, before breakfast, as labeled.
2. Take AOD-9604 sublingually or orally at a separate time, ideally in the evening or at least four to six hours after the PPI dose when gastric pH may have partially recovered.
3. Subcutaneous AOD-9604 at any time of day requires no scheduling adjustment around PPI dosing.

A 2021 review in Pharmaceutics confirmed that gastric pH returns toward baseline within six to eight hours after a single omeprazole dose in some patients, though this rebound is blunted with chronic daily use [22].

Patient Counseling Script

Patients should be told:

• If you inject AOD-9604, your PPI does not meaningfully affect how the peptide works.
• If you take AOD-9604 under your tongue or swallow it as a capsule, take it on an empty stomach and separate it by several hours from your omeprazole or pantoprazole.
• Report any new GI symptoms, muscle cramps, or changes in body composition response to your prescribing clinician.
• Do not stop your PPI without talking to the physician who prescribed it; acid rebound after abrupt PPI discontinuation can cause significant discomfort [23].

Special Populations

Patients With GERD or Barrett's Esophagus

These patients often require long-term, high-dose PPI therapy. Continuous acid suppression means gastric pH stays above 4.0 for most of the day. For this group, subcutaneous AOD-9604 is strongly preferred over oral formulations when both drugs are co-prescribed.

CYP2C19 Poor Metabolizers

This genotype produces substantially higher PPI plasma levels, leading to greater and more prolonged acid suppression [13]. A CYP2C19 poor metabolizer on omeprazole 40 mg daily may sustain gastric pH above 6.0 for extended periods [5]. For this subset of patients using oral AOD-9604 formulations, absorption variability is highest. Genotype-guided PPI selection (pantoprazole over omeprazole) may modestly reduce acid-suppression magnitude [6].

Older Adults

Adults over 65 already have reduced gastric acid secretion (achlorhydria affects an estimated 10 to 30 percent of this group) [24]. Adding a PPI on top of baseline hypochlorhydria further raises gastric pH. Subcutaneous administration is especially appropriate in this group for any injectable peptide therapy.

What Compounding Pharmacies and Prescribers Should Know

503A compounding pharmacies are permitted to prepare AOD-9604 for individual patients with a valid prescription. The FDA does not regulate compounded formulations under the same premarket approval standards applied to commercially manufactured drugs [25]. This means no manufacturer has submitted a formal drug interaction study to the FDA for AOD-9604. Prescribers relying on 503A compounded AOD-9604 must apply mechanistic reasoning and available peptide pharmacology literature rather than label-derived DDI data.

The Endocrine Society's 2023 position statement on peptide therapies notes that compounded peptides "lack the pharmacokinetic, safety, and efficacy data required to make evidence-based prescribing decisions" for many combinations [26]. That position reinforces the need for mechanistic reasoning and close patient follow-up when co-prescribing compounds like AOD-9604 with chronic medications like PPIs.